235 related articles for article (PubMed ID: 33281729)
1. Increased Cerebrospinal Fluid Uric Acid Levels in Guillain-Barré Syndrome.
Chang SH; Tian XB; Wang J; Liu MQ; Huang CN; Qi Y; Zhang LJ; Gao CL; Zhang DQ; Sun LS; Yang L
Front Neurol; 2020; 11():589928. PubMed ID: 33281729
[TBL] [Abstract][Full Text] [Related]
2. Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features.
Liu MQ; Wang J; Huang CN; Qi Y; Zhang LJ; Yi M; Chang SH; Sun LS; Yang L
Neurol Sci; 2021 Oct; 42(10):4249-4255. PubMed ID: 33598798
[TBL] [Abstract][Full Text] [Related]
3. Sural-sparing is seen in axonal as well as demyelinating forms of Guillain-Barré syndrome.
Umapathi T; Li Z; Verma K; Yuki N
Clin Neurophysiol; 2015 Dec; 126(12):2376-80. PubMed ID: 25743269
[TBL] [Abstract][Full Text] [Related]
4. Study on Electrophysiological Findings of Guillain Barre Syndrome Patients Attending the Department of Neurology in BSMMU.
Das S; Khan RK; Alam SM; Chowdhury NH; Das P
Mymensingh Med J; 2018 Jul; 27(3):631-640. PubMed ID: 30141456
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.
Wang XK; Zhang HL; Meng FH; Chang M; Wang YZ; Jin T; Mix E; Zhu J
Neurol Sci; 2013 May; 34(5):655-61. PubMed ID: 22526766
[TBL] [Abstract][Full Text] [Related]
6. A study on the role of serum uric acid in differentiating acute inflammatory demyelinating polyneuropathy from acute-onset chronic inflammatory demyelinating polyneuropathy.
Zhang W; Tao W; Wang J; Nie P; Duan L; Yan L
Eur J Neurol; 2024 May; 31(5):e16222. PubMed ID: 38356316
[TBL] [Abstract][Full Text] [Related]
7. Elevated blood and cerebrospinal fluid glucose levels affect the severity and short-term prognosis of Guillain-Barré syndrome.
Gong Q; Liu S; Xiao Z; Fu X; Lu Z
Neurol Res; 2022 Feb; 44(2):121-127. PubMed ID: 34382919
[TBL] [Abstract][Full Text] [Related]
8. Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome.
Yadegari S; Nafissi S; Kazemi N
Iran J Neurol; 2014 Jul; 13(3):138-43. PubMed ID: 25422732
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.
Bourque PR; Brooks J; Warman-Chardon J; Breiner A
J Neurol; 2020 Mar; 267(3):746-751. PubMed ID: 31734909
[TBL] [Abstract][Full Text] [Related]
10. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome.
Zhang LJ; Guo HY; Zhang DQ; Wang R; Li T; Li LM; Suo DM; Yang L
Clin Chim Acta; 2017 May; 468():5-9. PubMed ID: 28167198
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies.
Illes Z; Blaabjerg M
Handb Clin Neurol; 2017; 146():125-138. PubMed ID: 29110767
[TBL] [Abstract][Full Text] [Related]
12. Role of Anti-ganglioside Antibodies in the Diagnosis of Guillain-Barré Syndrome as an Alternate Investigation.
Saeed ML; Kaleem Baloch B; Mahmud SN; Khan MT; Qureshi MSS; Shad ZS; Hussain SW; Munawar K; Qadeer A; Abdullah A
Cureus; 2019 May; 11(5):e4625. PubMed ID: 31312551
[TBL] [Abstract][Full Text] [Related]
13. Guillain-Barré syndrome in children - High occurrence of Miller Fisher syndrome in East Asian region.
Chiu ATG; Chan RWK; Yau MLY; Yuen ACL; Lam AKF; Lau SWY; Lau AMC; Fung STH; Ma KH; Lau CWL; Yau MM; Ko CH; Tsui KW; Ma CK; Tai SM; Yau EKC; Fung E; Wu SP; Kwong KL; Chan SHS
Brain Dev; 2022 Nov; 44(10):715-724. PubMed ID: 35906115
[TBL] [Abstract][Full Text] [Related]
14. Axonal degeneration in Guillain-Barré syndrome: a reappraisal.
Berciano J
J Neurol; 2021 Oct; 268(10):3728-3743. PubMed ID: 32607643
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome: subtypes and predictors of outcome from India.
Kalita J; Misra UK; Goyal G; Das M
J Peripher Nerv Syst; 2014 Mar; 19(1):36-43. PubMed ID: 24456386
[TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome.
Arcila-Londono X; Lewis RA
Semin Neurol; 2012 Jul; 32(3):179-86. PubMed ID: 23117942
[TBL] [Abstract][Full Text] [Related]
17. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders.
Shu Y; Li H; Zhang L; Wang Y; Long Y; Li R; Qiu W; Lu Z; Hu X; Peng F
Brain Behav; 2017 Jan; 7(1):e00584. PubMed ID: 28127508
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Maimone D; Annunziata P; Simone IL; Livrea P; Guazzi GC
J Neuroimmunol; 1993 Aug; 47(1):55-61. PubMed ID: 8376548
[TBL] [Abstract][Full Text] [Related]
19. Elevated monocyte to high-density lipoprotein cholesterol ratio correlates with clinical severity in acute inflammatory demyelinating polyradiculoneuropathy patients.
Peng YF; Luo M; Zhang QS
Front Neurol; 2022; 13():955933. PubMed ID: 36237631
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cerebrospinal fluid protein level and electrophysiologic abnormalities in the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barré syndrome.
Jawaid W; Sana R; Umer SR; Nisa Q; Butt M; Shahbaz N
Ger Med Sci; 2021; 19():Doc12. PubMed ID: 34539302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
